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 Prostaglandins (PGs) are a family of lipid signaling 
mediators generated by cyclooxygenase (COX) enzymes, 
COX-1 and -2. They play central roles in health, as well as 
in diseases including cancer and atherosclerosis. Until re-
cently, they were considered to only exist as free acid me-
diators, secreted from cells to activate G-protein coupled 
receptors in a paracrine manner. In 2005, Kozak et al. 
( 1, 2 ) showed prostaglandins E 2 and D 2 (PGE 2 , PGD 2 ) 
were generated in macrophage cell lines from COX-2 oxi-
dation of endogenous arachidonyl-glycerol (2-AG) and 
arachidonyl-ethanolamide (AEA). The products signal dif-
ferently to free PGE 2 and D 2 ; for example, PGE 2 -G mobi-
lizes calcium rapidly in a PGE 2 -independent manner, 
indicating they are chemically and functionally distinct 
from their free acid analogs ( 3, 4 ). 
 Oxidized phospholipids (oxPLs) were originally charac-
terized as nonenzymatically-generated species present in 
atheromatous plaque that display potent immunomodula-
tory activities ( 5–7 ). Recent studies have indicated that 
they are also generated in a highly specifi c manner by cel-
lular lipoxygenases (LOXs) in neutrophils, monocytes and 
platelets ( 8–14 ). Also, oxidized cholesteryl esters formed 
by 15-lipoxygenase in macrophages can transfer the oxi-
dized fatty acyl group to phospholipids ( 15 ). However, oxPLs 
generated by COX isoforms have not been described. 
 Abstract  Oxidized phospholipids (oxPLs) generated nonen-
zymatically display pleiotropic biological actions in infl amma-
tion. Their generation by cellular cyclooxygenases (COXs) is 
currently unknown. To determine whether platelets generate 
prostaglandin (PG)-containing oxPLs, then characterize their 
structures and mechanisms of formation, we applied precur-
sor scanning-tandem mass spectrometry to lipid extracts of 
agonist-activated human platelets. Thrombin, collagen, or ion-
ophore activation stimulated generation of families of PGs 
comprising PGE 2 and D 2 attached to four phosphatidyletha-
nolamine (PE) phospholipids (16:0p/, 18:1p/, 18:0p/, and 
18:0a/). They formed within 2 to 5 min of activation in a cal-
cium, phospholipase C, p38 MAP kinases, MEK1, cPLA 2 , and 
 src tyrosine kinase-dependent manner (28.1 ± 2.3 pg/2 × 10 8 
platelets). Unlike free PGs, they remained cell associated, sug-
gesting an autocrine mode of action. Their generation was 
inhibited by in vivo aspirin supplementation (75 mg/day) or in 
vitro COX-1 blockade. Inhibitors of fatty acyl reesterifi cation 
blocked generation signifi cantly, while purifi ed COX-1 was un-
able to directly oxidize PE in vitro. This indicates that they 
form in platelets via rapid esterifi cation of COX-1 derived 
PGE 2 /D 2 into PE.  In summary, COX-1 in human platelets 
acutely mediates membrane phospholipid oxidation via for-
mation of PG-esterifi ed PLs in response to pathophysiologi-
cal agonists. —Aldrovandi, M., V. J. Hammond, H. Podmore, 
M. Hornshaw, S. R. Clark, L. J. Marnett, D. A. Slatter, 
R. C. Murphy, P. W. Collins, and V. B. O’Donnell.  Human 
platelets generate phospholipid-esterifi ed prostaglandins 
via cyclo oxygenase-1 that are inhibited by low dose aspirin 
supplementation.  J. Lipid Res . 2013.  54: 3085–3097. 
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(solvent B), with fl ow rate 1 ml.min   1 (16) . Solvent B was increased 
from 20% to 42.5% over 50 min, then increased to 90% over 
10.5 min, held for 5 min, then returned to 20% over 1 min. Equil-
ibration time between runs was 14 min. Settings were DP -50 V, CE 
-26 V. The following transitions were monitored:  m/z 351.2  → 271 
(8-isoPGE 2 , 11  -PGE 2 , PGE 2 and PGD 2 ),  m/z 355.2  → 275.3 
(PGE 2 -d4 and PGD 2 -d4). 
 Reverse-phase LC-MS/MS of esterifi ed eicosanoids 
 For analysis of esterifi ed prostaglandins in MRM mode, lipid ex-
tracts were separated by reverse-phase HPLC using a Luna 3   m C18 
( 2 ) 150 mm × 2 mm column (Phenomenex) with a gradient of 50–
100% B over 10 min followed by 30 min at 100% B (A, methanol/
acetonitrile/water, 1 mmol/L ammonium acetate, at 60:20:20; 
B, methanol, 1 mmol/L ammonium acetate) with flow rate 
200   l min  –1 . MS was carried out using a Sciex 4000 Q-Trap, using 
DP -140 V, CE -45 V. Lipids were monitored as parent  m/z to 
daughter ( m/z 351.2 or 271.2, as appropriate), with dwell time 
200 ms. For analysis of lipids by full scan using accurate mass, lipids 
were separated by reverse-phase HPLC coupled to an Orbitrap 
Velos, on a C18 Hypersil Gold, 1.9 µm, 100 × 2.1 mm column using 
a gradient of 50–100% B over 10 min followed by 15 min at 100% B, 
then resetting to starting conditions over 5 min (A, methanol/
acetonitrile/water, 1 mmol/L ammonium acetate, 60:20:20; B, 
methanol, 1 mmol/L ammonium acetate) with a fl ow rate of 
200   l min  –1 . Analysis was performed using heated ESI in negative 
ion mode at sheath, auxiliary, and sweep gas fl ows of 30, 10, and 0, 
respectively. The capillary and source heater temperatures were set 
to 275 and 250°C, respectively. Resolving power of 30,000 in FTMS 
mode was used. Negative MS/MS spectra were acquired using higher 
energy collision-induced-dissociation. Data-dependent MS ( 3 ) of  m/z 
351 was carried out in ITMS mode on the LTQ in negative mode. 
 Isolation and activation of human platelets 
 All blood donations were approved by the Cardiff University 
School of Medicine Ethics Committee, were with informed consent 
(SMREC 12/37, SMREC 12/10), and were according to the Dec-
laration of Helsinki. For studies on isolated platelets, whole blood 
was collected from healthy volunteers free from nonsteroidal anti-
infl ammatory drugs for at least 14 days into acid-citrate-dextrose 
(ACD; 85 mmol/L trisodium citrate, 65 mmol/L citric acid, 
100 mmol/L glucose) (blood:ACD, 8.1:1.9, v/v) and centrifuged 
at 250  g for 10 min at room temperature. Platelet-rich plasma was 
collected and centrifuged at 900  g for 10 min, and the pellet 
resuspended in Tyrode’s buffer (134 mmol/L NaCl, 12 mmol/L 
NaHCO 3 , 2.9 mmol/L KCl, 0.34 mmol/L Na 2 HPO 4 , 1.0 mmol/L 
MgCl 2 ,10 mmol/L Hepes, 5 mmol/L glucose, pH 7.4) contain-
ing ACD (9:1, v/v). Platelets were centrifuged at 800  g for 10 min 
then resuspended in Tyrode’s buffer at 2 × 10 8 .ml   1 . Platelets 
were activated at 37°C in the presence of 1 mmol/L CaCl 2 for 
varying times, with 0.2 unit.ml   1 thrombin, 10   g/ml collagen, 
10   mol/L A23187, 20   mol/L TFLLR-NH 2 , or 150   mol/L 
AY-NH 2 before lipid extraction as below. Experiments involv-
ing signaling inhibitors (1 mmol/L aspirin, 1 µmol/L SC-560, 
10 µmol/L indomethacin, 2 µmol/L OOEPC, 50 nmol/L BEL, 
50 nmol/L cPLA 2   i, 75 µM thimerosal, 7   M triascin C, 1 mM 
EGTA, 10 µM 1,2-bis-( o -aminophenoxy) ethane- N,N,N  ′ ,N  ′ - tetraacetic 
acid tetrakis-acetoxymethyl ester (BAPTA/AM), 100 nM wort-
mannin, 100 nmol/L Gö 6850, 50   mol/L PD98059, 50 µmol/L 
PP2, 100 nmol/L p38 mitogen-activated protein kinase inhibitor, 
and 5 µM U-73122) included a 10 min preincubation at room 
temperature. In some experiments, calcium was omitted from 
buffers. For separation of cells from microparticles, platelets 
were centrifuged at 970  g for 5 min then supernatants respun at 
16,060  g for 5 min. For aspirin supplementation, blood samples 
were fi rst obtained following a 14-day NSAID-free period for 
Furthermore, whereas COX-2 can oxidize AEA and 2-AG, 
the constitutive isoform COX-1 has not been shown to be 
a source of any esterifi ed eicosanoids before. Herein, we 
used a targeted lipidomic approach to demonstrate that 
human platelets generate phospholipid (PL)-esterifi ed 
PGE 2 and PGD 2 on agonist activation. Their synthesis is 
highly regulated, involving receptors and a number of key 
intracellular signaling pathways. Thus, oxPLs can be gen-
erated acutely via COX-1 and represent a new family of 
lipids from this important vascular signaling pathway. 
 MATERIALS AND METHODS 
 Materials 
 Lipid and fatty acid standards were purchased from Avanti 
Polar Lipids (Alabaster, AL) or Cayman Chemical (Cayman 
Islands). HPLC grade solvents were from Thermo Fisher Scientifi c 
(Hemel Hempstead, UK). Protease-activated receptor (PAR)-1 
and -4 agonists were from Tocris Biosciences (Bristol, UK). Tri-
acsin C, PGE 2 , PGD 2 , 8-iso-PGE 2 , and 11  -PGE 2 were from Enzo 
Life Sciences (Exeter, UK). COX-1 inhibitor (Sc-560) PGE2-d4, 
PGD2-d4, and AA-d8 were from Cayman Chemical. Platelet sig-
naling inhibitors [PP2, oleyloxyethylphosphocholine (OOEPC), 
bromoenol lactone (BEL), cytosolic phospholipase A 2   (cPA 2   ) 
inhibitor (N-((2S,4R)-4-(Biphenyl-2-ylmethyl-isobutyl-amino)-
1-[2-(2,4-difl uorobenzoyl)-benzoyl]pyrrolidin-2-ylmethyl}-3-[4-
(2,4-dioxothiazolidin-5-ylidenemethyl)-phenyl]acrylamide, HCl), 
U73112, wortmannin, and p38 mitogen-activated protein kinase 
inhibitor] were from Calbiochem. All other reagents were from 
Sigma-Aldrich unless otherwise stated. 
 Precursor LC-MS/MS 
 Lipid extracts were separated by reverse-phase HPLC using a 
Luna 3   m C18 ( 2 ) 150 × 2 mm column (Phenomenex, Tor-
rance, CA) with a gradient of 50–100% B over 10 min followed by 
30 min at 100% B (A, methanol:acetonitrile:water, 1 mmol/L 
ammonium acetate, 60:20:20; B, methanol, 1 mmol/L ammo-
nium acetate) with a fl ow rate of 200   l.min   1 . Settings were DP 
-140 V, CE -45 V. Spectra were acquired scanning Q1 from 650 to 
950 atomic mass units (amu) over 5 s with Q3 set to  m/z 351.2. 
 Normal-phase HPLC of phospholipids 
 Phospholipids were separated according to headgroup using 
normal-phase HPLC, on a Spherisorb S5W 150 × 4.6 mm column 
(Waters Ltd. Herts, UK) with a gradient of 50 - 100% B over 25 min 
(A, hexane:propan-2-ol, 3:2; B, solvent A:water, 94.5:5.5) at a fl ow 
rate of 1.5 ml.min   1 . Absorbance was monitored at 205 nm and 
products identifi ed using a mixture of standard phospholipids 
(Sigma-Aldrich). Fractions were collected at 30 s intervals for subse-
quent analysis by direct injection ESI/MS/MS on a Sciex 4000 
Q-Trap. This was performed by injecting 20 µl of each fraction un-
der fl ow (1 ml.min   1 ) in methanol into the electrospray source, with 
specifi c multiple reaction monitoring (MRM) transitions monitored 
as parent of  m/z 770.6, 796.6, 798.6 and 814.6 [M-H]    , fragmenting 
to daughter of  m/z 351.2. Settings were DP -140 V, CE -45 V. 
 Reverse-phase LC-MS/MS of PG isomers 
 Separation of 8-isoPGE 2 , 11  -PGE 2 , PGE 2 , and PGD 2 was con-
ducted using a C18 Spherisorb ODS2, 5   m, 150 × 4.6 mm column 
(Waters, UK). The solvent system was composed of 0.1% formic 
acid in water (solvent A) and 0.1% formic acid in acetonitrile 
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 Lipid extraction 
 5 ng PGE 2 -d4, PGD 2 -d4, and di-14:0-phosphatidylethanolamine 
were added to samples before extraction as internal standards. 
Lipids were extracted by adding a solvent mixture [1 mol/L acetic 
acid, isopropyl alcohol, hexane (2:20:30, v/v/v)] to the sample at 
baseline determinations of eicosanoids. Subjects were adminis-
tered 75 mg/day aspirin for 7 days then provided a second blood 
sample. Platelets were isolated and activated in vitro using 
0.2 U/ml thrombin, as described above, then lipids extracted as 
described below. Exclusion criteria was a known sensitivity to 
aspirin. 
 Fig.  1. Identifi cation of esterifi ed PGs in human platelets and analysis of PGE 2 /D 2 -PE using LC/MS/MS .  A: Precursor scanning demon-
strates lipids with  m/z 351.2 eluting during LC/MS/MS. Total lipid extracts from washed human platelets activated with 0.2 U/ml of throm-
bin for 30 min at 37°C were separated on the Q-Trap platform using LC/MS/MS as described in Materials and Methods , with online 
negative precursor scanning for  m/z 351.2. *, region of LC trace where ions appear that are elevated by thrombin stimulation. Control, 
broken line. B: Identifi cation of ions that generate  m/z 351.2 daughter ions. Shown is a negative MS scan of region marked * in A. Scan 
shows ions eluting between 19 and 24 min. C: Characterizing phospholipid headgroups of esterifi ed PL. Lipid extracts from thrombin-
activated platelets were separated on normal-phase HPLC, as described in Materials and Methods, with fractions collected at 30 sec inter-
vals. Twenty microliters of each fraction was analyzed specifi c parent  →  m/z 351.2 MRM transitions. PL class elution was determined using 
commercial phospholipid standards. Panels D–G: LC/MS/MS of PGE 2 /D 2 -PEs. Platelet lipid extracts were separated using LC/MS/MS as 
described in Materials and Methods and detected on the Q-Trap platform by parent  →  m/z 271.2. 
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 Fig.  2. Generation of free and esterifi ed PGs by agonist-activated platelets. Generation of PGE 2 /D 2 -PEs and free prostaglandins in re-
sponse to pathophysiological agonists. Washed platelets were activated for varying times as shown, and lipids were extracted and analyzed 
using LC/MS/MS as described in Materials and Methods. Platelets were activated using 0.2 U/ml thrombin and PGE 2 /D 2 -PEs were deter-
mined (A). Platelets were activated using 10 µg/ml of collagen (B). Platelets were activated using 10 µg/ml of collagen and 0.2 U/ml of 
thrombin (C). Platelets were activated using 10 µmol/L A23187 (D). Levels of PGE 2 /D 2 -PE are expressed as ratio analyte to internal stan-
dard with experiments repeated at least three times on different donors (n = 3, mean ± SEM). 
 Scheme  1. Structures of PGE 2 /D 2 -PE molecules identifi ed in human platelets. 
a ratio of 2.5 ml to 1 ml sample, vortexing, and then adding 
2.5 ml of hexane ( 14 ). After vortexing and centrifugation, lipids 
were recovered in the upper hexane layer. The samples were 
then reextracted by addition of an equal volume of hexane. 
The combined hexane layers were dried and analyzed for free or 
esterifi ed PGs using LC-MS/MS as below. 
 Reverse-phase LC-MS/MS of free eicosanoids 
 Lipids were separated on a C18 Spherisorb ODS2, 5   m, 150 × 
4.6 mm column (Waters, Hertfordshire, UK) using a gradient of 
50–90% B over 10 min (A, water:acetonitrile:acetic acid, 75:25:0.1; 
B, methanol:acetonitrile:acetic acid, 60:40:0.1) with a fl ow rate of 
1 ml.min   1 . Products were quantitated by LC-MS/MS electrospray 
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 Fig.  3. Esterifi ed prostaglandins are retained by platelets while free PGE 2 and PGD 2 are primarily secreted, and generation of free and 
esterifi ed PGs is sensitive to COX-1 inhibition in vitro and in vivo. A, B: Esterifi ed PGs are retained by platelets. Washed human platelets 
were activated with 0.2 U/ml thrombin for 30 min before centrifugation at 970  g . The supernatant was centrifuged at 16,060  g to pellet 
microparticles before lipid extraction and analysis by LC/MS/MS. C, D: Esterifi ed and free PGE 2 /D 2 generation is sensitive to aspirin 
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822.7  → 278.2 (PGE 2 /D 2 -PE-d8),  m/z 351.2  → 271 (PGE 2 and 
PGD 2 ),  m/z 359.2  → 278.2 (PGE 2 -d8 and PGD 2 -d8),  m/z 355.2  → 
275.3 (PGE 2 -d4 and PGD 2 -d4). 
 Statistics 
 Data are representative of at least three separate donors with 
samples run in triplicate for each experiment. Data is expressed 
as mean ± SEM of three separate determinations. Statistical sig-
nifi cance was assessed using an unpaired, two-tailed Student’s 
 t -test. Where the difference between more than two sets of data 
was analyzed, one-way ANOVA was used followed by Bonferroni 
multiple comparisons test as indicated in the legends.  P < 0.05 
was considered statistically signifi cant. 
 RESULTS 
 Precursor scanning LC/MS/MS identifi es esterifi ed PGs 
in lipid extracts from thrombin-activated platelets 
 To identify PGs attached to larger functional groups, 
washed human platelets were activated using thrombin, 
then lipids extracted and analyzed using precursor-LC/
MS/MS for  m/z 351.2, the carboxylate anion of several PG 
species. Multiple ions eluted between 16 and 24 min that 
elevated on thrombin activation ( Fig. 1A ). Spectra ac-
quired in this time window demonstrated four prominent 
ions at  m/z 770, 796, 798, and 814, ( Fig. 1B ). These could 
represent either PE or phosphatidylcholine (PC), with 
PGs attached ( 20 ). Next, lipids were separated into PE and 
PC fractions using normal-phase HPLC and analyzed by fl ow 
injection LC/MS/MS, using parent-to-daughter transitions 
(parent  m/z 770, 796, 798 and 814, daughter  m/z 351.2). 
All four coeluted with the same retention time as a PE 
standard in the 7-9 min fraction ( Fig. 1C ). Thus, the ions 
are proposed as PEs containing 16:0p, 18:1p, 18:0p, and 
18:0a at sn1 and a PG at sn2, and are termed prostaglan-
din-PEs (PG-PEs). Further analysis using MS/MS, MS 3  and 
saponifi cation followed by PG analysis demonstrated that 
one family of the lipids represents PGE 2  and PGD 2  esteri-
fi ed to PE ( Scheme 1 ) (see supplementary data). 
 As we were unable to use  m/z 351.2 for MRM detection 
of PGE 2 - and PGD 2 -PE (carboxylate daughter ion did not 
survive collision-induced-dissociation, as described in full 
in supplementary data), a method was established using 
 m/z 271.1 as daughter ion ( Fig. 1 D–G ). However, because 
PGE 2 and PGD 2 -PE lipids coelute on our system, in sub-
sequent studies, each PGE 2 - and PGD 2 -PE pair (i.e., the 
same PE species) are reported as a single species. 
ionization on a Sciex 4000 Q-Trap using parent-to-daughter transi-
tions of  m/z 351.2 [M-H] - to  m/z 271 for PGE 2 and PGD 2 ,  m/z 355.2 
to 275.3 for PGE 2 -d4 and PGD 2 -d4 with declustering potential 
of -55 and collision energies of -26 V. Products were identifi ed and 
quantifi ed using standards run in parallel under the same condi-
tions. The following transitions were monitored:  m/z 351.2  → 271 
(PGE 2 and PGD 2 ),  m/z 355.2  → 275.3 (PGE 2 -d4 and PGD 2 -d4). 
 Reverse-phase LC-MS/MS of esterifi ed eicosanoids 
 For analysis of PGE 2 /D 2 -phosphatidylethanolamines (PEs) in 
MRM mode, lipid extracts were separated by reverse-phase HPLC 
using a Luna 3   m C18 ( 2 ) 150 mm × 2 mm column (Phenome-
nex) with a gradient of 50–100% B over 10 min followed by 
30 min at 100% B (A, methanol/acetonitrile/water, 1 mmol/L 
ammonium acetate, at 60:20:20; B, methanol, 1 mM ammonium 
acetate) with fl ow rate 200   l min  –1 . MS was carried out using a 
Sciex 4000 Q-Trap, using declustering potential -140 V, collision 
energy -45 V. Lipids were monitored as parent  m/z to daughter 
( m/z 271.2, as appropriate), with dwell time 200 ms. 
 Phospholipase A 2 hydrolysis 
 Platelet lipid extracts were dried using N 2 then resuspended in 
1 ml buffer [150mmol/L NaCl, 5mmol/L CaCl 2 , 10 mmol/L Tris 
(Trizma base), pH 8.9]. Two hundred micrograms snake venom 
phospholipase A 2 (PLA 2 ) from Sigma-Aldrich was added and in-
cubated for 60 min at 37°C. Lipids were reextracted as described 
above using hexane:isopropanol:acetic acid. 
 Oxidation of free and phospholipid-esterifi ed 
arachidonate by purifi ed/recombinant COX-1 and COX-2 
 Apo-COX-1 was purifi ed from ram seminal vesicles and stored 
at 3.83 mg·ml   1 in 80 mMTris, pH 7.8, at   80°C ( 17, 18 ). Wild-
type murine COX-2 (recombinant) was generated and purifi ed 
as described (10.61 mg·ml   1 ) ( 19 ). Both enzymes were quanti-
fi ed using Bicinchoninic Acid (BCA) Protein Assay Kit (Thermo 
Fisher Scientifi c), according to manufacturer’s instructions. For 
heme reconstitution, Apo-COX-1 or -2 (35 µg) was preincubated 
on ice for 20 min with 2 molar equivalents of hematin in phos-
phate buffer (100 mM potassium phosphate buffer, pH 7.4). 
Then, 3.5   g of the reconstituted enzyme was added to 1 ml 
phosphate buffer and 500 µmol/L phenol and incubated for 
3 min at 37°C in the presence of 150 µM arachidonate (AA, or 
AA-d8). In some experiments, the same amount of AA was re-
placed with 1-stearoly-2-arachidonyl-PE (SAPE). The reaction was 
stopped by addition of ice-cold lipid extraction solvent and im-
mediate extraction of lipids, after addition of 5 ng each of 
PGE 2 -d4 and PGD 2 -d4 as internal standards, as described earlier. 
PGE 2 and D 2 were quantifi ed by LC-MS/MS analysis as described 
earlier. In some experiments, 10   mol/L of the metal chelator 
diethylenetriaminepentaacetic acid (DTPA) was added to the re-
action just before the addition of holoCOX-1. The following 
transitions were monitored:  m/z 634.4  → 227.2 (di-14:0-phos-
phatidylethanolamine),  m/z 814.7  → 271.2 (PGE 2 /D 2 -PE),  m/z 
in vitro. Platelets were incubated for 15 min with 1 mM aspirin prior to thrombin activation (0.2 U/ml, 30 min) followed by lipid extraction and 
analysis of free and esterifi ed PGE 2 /D 2 using LC/MS/MS. E, F: Esterifi ed and free PGE 2 /D 2 generation is sensitive to COX inhibitors. 
Platelets were incubated for 10 min with 1   M Sc-560 or 10   M indomethacin prior to thrombin activation (0.2 U/ml for 30 min) followed 
by lipid extraction and analysis of free and esterifi ed PGE 2 /D 2 using LC/MS/MS. For all experiments described above, n = 3; mean ± SEM; 
data representative of three independent donors. * P < 0.05, ** P < 0.01, and *** P < 0.001 versus control using ANOVA and Bonferroni 
post hoc test. G, H: Free and esterifi ed PGE 2 /D 2 formation in vivo is blocked by aspirin. Blood was obtained following a 14-day NSAID-free 
washout period for isolation of washed platelets and determination of free and esterifi ed PGE 2 /D 2 levels, as described in Materials and 
Methods, following activation using 0.2 U/ml thrombin for 30 min. Subjects then received 75 mg/day aspirin for 7 days before donation 
of a second blood sample and repeat determination of free and esterifi ed PGE 2 /D 2 levels. Data is representative of fi ve independent donors 
(n = 5, mean ± SEM); * P < 0.05, ** P < 0.01, and *** P < 0.001 versus control using ANOVA and Bonferroni post hoc test. Levels of PGE 2 /
D 2 -PE are expressed as ratio analyte to internal standard. Levels of free PGE 2 and PGD 2 are expressed as ng/2 × 10 
8 platelets. 
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 Human platelets acutely generate PGE 2 /D 2 -PEs on 
agonist activation that remain cell-associated 
 Temporal studies showed that PGE 2 /D 2 -PEs formed on 
activation with thrombin, collagen, or ionophore, similar to 
free PGE 2 and PGD 2 ( Fig. 2A–D ).  While 16:0p-, 18:0p-, and 
18:1p- species were always found, 18:0a/PGE 2 /D 2 -PE was 
sometimes under the limit of detection. Both free and es-
terifi ed PGE 2 and PGD 2 were already detectable after 2 min 
activation. However, PGE 2 /D 2 -PEs levels peaked around 
10 to 30 min before starting to decline, unlike free PGs, 
which remained stable or continue to increase up to 3 h af-
ter platelet activation ( Fig. 2A–D ). As standards are not yet 
available, we isolated PGE 2 /D 2 -PEs from platelets and quan-
tifi ed PG attached following hydrolysis and LC/MS/MS. 
Using this, we determined after 30 min of thrombin activa-
tion, mean values for esterifi ed PGE 2 /D 2 -PE were 7.05 ± 0.7, 
8.2 ± 0.9, 9.5 ± 0.5 and 3.3 ± 0.2 pg/2 × 10 8 platelets (mean ± 
SEM, fi ve genetically unrelated donors) for the 16:0p/, 
18:1p/, 18:0p, and 18:0a/ forms, respectively, with a total for 
all four PE species of 28.1 ± 2.3 pg/2 × 10 8 cells. PGE 2 /D 2 -PE 
was primarily retained (  85%) by the platelets with small 
amounts appearing in either microparticles or superna-
tant ( Fig. 3A ). In contrast,   95% of free PGE 2 and PGD 2 
was released into the supernatant ( Fig. 3B ). 
 PGE 2 /D 2 -PE generation is blocked by COX-1 inhibition 
in vitro and in vivo 
 In vitro, several COX inhibitors including indometha-
cin, aspirin, and the COX-1 inhibitor, SC 560, completely 
inhibited PGE 2 /D 2 -PE formation as well as free PGE 2 /D 2 
( Fig. 3C–F ). Furthermore, a 7 day supplementation with 
COX-1 selective low dose aspirin in vivo inhibited genera-
tion of both free and esterifi ed PGE 2 /D 2 by washed plate-
lets in response to thrombin ( Fig. 3G, H ). 
 PGE 2 /D 2 -PE forms in platelets via esterifi cation of free 
PGE 2 /D 2 into PE 
 To determine whether PGE 2 /D 2 -PE generation by plate-
lets is via direct oxidation of PE or fast esterifi cation of newly 
formed eicosanoid, PLA 2 , and fatty acyl reacylation path-
ways were inhibited and the ability of purifi ed and recombi-
nant COX isoforms to oxidize AA-containing PE in vitro 
tested. Inclusion of several PLA 2 inhibitors demonstrated 
requirement for cPLA 2 (cPLA 2i ), but not iPLA 2 BEL or 
sPLA 2 OOEPC ( Fig. 4A , C ). Similar results were seen for 
free PG ( Figs. 4B, D ). Inhibition of fatty acylation using 
thimerosal or triascin C showed approximately 50% inhi-
bition of PGE 2 /D 2 -PE generation ( Fig. 4E, F ). In separate 
experiments, platelets were supplemented with PGE 2 -d4 
or AA-d8, at amounts similar to those generated during 
platelet activation, to determine whether exo genous lipids 
are incorporated into PE during the timescale of platelet 
activation. However, platelets never generated deuterated-
PGE 2 /D 2 -PEs in our experiments (not shown). 
 Purifi ed COX isomers generated PGE 2 and D 2 from AA 
with a 2:1 predominance of PGE 2 over PGD 2 , due to decom-
position of enzymatically-generated PGH 2 , similar to what is 
observed in platelets ( Figs. 2, 4G, H ). A small amount of 
PGE 2 /D 2 -PE was detected in 18:0a/20:4-PE (SAPE), even 
though it was a freshly opened vial, and this was increased 
by hematin (the COX-1 cofactor, added alone as control) 
through nonenzymatic oxidation ( Fig. 4I ). However, COX-1 
did not elevate PGE 2 /D 2 -PE further, indicating it cannot di-
rectly oxidize SAPE. However, when SAPE was added dur-
ing COX-1 oxidation of AA, a small formation of PGE 2 /
D 2 -PEs was observed ( Fig. 4I ). Where AA-d8 was used in-
stead of AA, deuterated forms of esterifi ed PGs were not 
detected, indicating that esterifi ed PGs originated directly 
via SAPE oxidation (not shown). Metal chelation (DTPA) 
did not inhibit formation, demonstrating that Fenton chem-
istry was not involved ( Fig. 4I ). Thus, it is likely that AA-
derived radicals escaping from the COX-1 active site during 
turnover oxidize PE in a metal-independent manner gener-
ating isoprostane-PEs that include PGE 2 /D 2 -PEs. This may 
also occur in platelets as a minor pathway for esterifi ed iso-
prostane formation, but it is unlikely to account for the ma-
jority of the PGE 2 /D 2 -PE formation as esterifi ed isoprostanes 
were not detected in our experiments. 
 Collectively, the requirement for cPLA 2 and COX-1 for 
platelet PGE 2 /D 2 -PE generation indicates that COX-1 oxi-
dation of AA is required. Inhibition by triascin C and thime-
rosal suggest that PGE 2 /D 2 -PE generation in platelets 
occurs via reesterifi cation of PGs. However, only endoge-
nously generated PG is utilized, suggesting tight coupling 
between PGE 2 /D 2 synthesis and incorporation into PE. 
 Fig.  4. Generation of PGE 2 /D 2 -PEs requires cPLA 2 and esterifi cation of free eicosanoids. A-D: Generation of free and esterifi ed PGE 2 /D 2 
requires cPLA 2 but not other PLA 2 isoforms . Washed human platelets were incubated for 10 min with each phospholipase A 2 inhibitor 
prior to thrombin activation (0.2 U/ml for 30 min) followed by lipid extraction and analysis by LC/MS/MS. Inhibitors: cytosolic PLA 2 
(cPLA 2   ) inhibitor (cPLA 2   i, 50 nmol/L), Ca 
2+ -dependent secretory PLA 2 (sPLA 2 ) inhibitor (OOEPC2, 2 µmol/L), Ca 
2+ -independent in-
tracellular PLA 2 (iPLA 2 ) inhibitor (BEL, 50 nmol/L) or vehicle (DMSO, 0.5%). E, F: Inhibition of PGE 2 /D 2 -PE, by thimerosal or triascin 
C. Washed platelets were incubated for 30 min at 37°C with 75 µmol/L thimerosal or 7 mmol/L triascin C prior to thrombin activation 
(0.2 U/ml for 30 min) followed by lipid extraction and analysis using LC/MS/MS. For all experiments, n = 3; mean ± SEM; data are repre-
sentative of three independent donors. * P < 0.05, ** P < 0.01, and *** P < 0.001 versus control using ANOVA and Bonferroni post hoc test. 
G, H: COX isoforms generate a 2:1 ratio of PGE 2 :PGD 2 in vitro. 3.5   g of purifi ed ovine COX-1 and 3.5   g recombinant murine COX-2 
were incubated at 37°C for 3 min with 150 µM of AA before lipid extraction and analysis using LC/MS/MS as described in Materials and 
Methods. PGE 2 and PGD 2 are expressed as micrograms/3.5   g enzyme formed over 3 min (n = 3, mean ± SEM). I: PE is oxidized to PGE 2 /
D 2 -PE during oxidation of AA by COX-1. Purifi ed ovine Apo-PGHS-1 was reconstituted with hematin, ratio 2:1 (hematin: Apo-PGHS-1). 3.5   g 
of purifi ed ovine COX-1 was incubated at 37°C for 3 min with the following substrates: 150 µmol/L of AA; 150 µmol/L SAPE; liposomes 
containing AA and SAPE, in the presence or absence of 10   M DTPA, before lipid extraction and analysis using LC/MS/MS as described 
in Materials and Methods. Levels of PGE 2 /D 2 -PE are expressed as ratio analyte to internal standard/3.5   g enzyme generated over 3 min. 
PGE 2 and PGD 2 are expressed as micrograms/3.5   g enzyme generated over 3 min (n = 3, mean ± SEM). 
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 Generation of PGE 2 /D 2 -PE requires PARs, intracellular 
calcium mobilization, src-tyrosine kinases, and MEK1, 
but not PI3-kinase, whereas PKC exerts negative 
feedback inhibition on generation 
 Thrombin activates platelets via PAR1 and PAR4. Pep-
tide agonists for either receptor, TFLLR-NH 2 (PAR1) or 
AY-NH 2 (PAR4), stimulated generation of both esterifi ed 
and free PGE 2 /D 2 ( Fig. 5A , B ).  Generation of PGE 2 /D 2 -PE 
and free PGE 2 /D 2 in response to thrombin was inhibited 
by the cytosolic calcium chelator BAPTA/AM, but not by 
chelation of extracellular calcium by EGTA, implicating 
calcium mobilization from intracellular stores ( Fig. 5C, D ). 
Inhibition of PI3-kinase (wortmannin) was without effect, 
while blocking PKC (Gö 6850) significantly enhanced 
PGE 2 /D 2 -PE formation ( Fig. 5E,F ). This indicates that 
PKC exerts a negative feedback effect on free and esteri-
fi ed PGE 2 /D 2 formation. Several agents effectively blocked 
generation including: U-73122, PD98059, PP2 and p38 
MAP kinases inhibitor, implicating phospholipase C, MEK1, 
 src -tyrosine kinases and p38 MAP kinases, respectively 
( Fig. 5E-H ). Collectively, the data indicate a highly coordi-
nated receptor and intracellular signaling pathway that 
is similar for both free and PE-esterifi ed prostaglandins 
( Scheme 2 ). 
 DISCUSSION 
 Herein, we showed that agonist-activated human plate-
lets generate families of oxPLs via COX-1 that comprise 
esterifi ed PGs, specifi cally PGE 2 and PGD 2 attached to PE. 
They form through a coordinated sequence of receptor 
and intracellular signaling pathways. We defi ned a new 
group of oxPLs and COX products, which form in plate-
lets in response to pathophysiological agonists. OxPLs are 
families of bioactive lipids generated by both enzymatic 
and nonenzymatic pathways in vascular and immune cells 
( 3, 7, 9–11, 13, 14 ). Up to now, it has not been considered 
that COX is a source of these; thus, this represents the fi rst 
example of crosstalk between these two key lipid signaling 
pathways. It is also a new fi nding for COX-1, which has not 
been shown as a source of esterifi ed PGs before. 
 PGE 2 /D 2 -PEs originated from COX-1 as their genera-
tion was sensitive to pharmacological inhibitors of this 
pathway both in vitro and in vivo. The primary product of 
COX-1, PGH 2 , is unstable in aqueous milieu, and in platelets, 
 Fig.  5. Elucidation of pathways involved in esterifi ed and free PGE 2 /D 2 generation by human platelets. A, B: Esterifi ed and free PGE 2 /D 2 s 
are generated via PAR-1 and PAR-4 receptor stimulation. Washed platelets were activated with a PAR-1 agonist, TFLLR-NH 2 (20   mol/L), 
and/or a PAR-4 agonist AY-NH 2 (150   mol/L) for 30 min before lipid extraction and LC/MS/MS analysis as described in Materials and 
Methods. C, D: Cytosolic Ca 2+ is required for thrombin-stimulated generation of esterifi ed and free PGE 2 /D 2 . Washed platelets were incu-
bated for 10 min with each inhibitor prior to thrombin activation (0.2 U/ml for 30 min) before lipid extraction and analysis as described 
in Materials and Methods. E-H: Phospholipase C, MEK1, p38 MAP kinases and  src tyrosine kinases are required for thrombin-stimulated 
generation of PGE 2 /D 2 -PEs . Washed human platelets were incubated for 10 min with inhibitors prior to thrombin (0.2 U/ml, 30 min) fol-
lowed by lipid extraction and analysis for free and esterifi ed PGE 2 /D 2 . Inhibitors used are as follows: PI3 kinase (wortmannin, 100 nmol/L), 
protein kinase C (Gö 6850, 100 nmol/L), MEK1 (PD98059, 50 µmol/L),  src -family tyrosine kinase (PP2, 50 µmol/L), p38 MAP kinase in-
hibitor (p38i, 100 nmol/L), and phospholipase C (U-73112, 5 µmol/L), or vehicle (DMSO, 0.5%). For all experiments, n = 3; mean ± SEM; 
data are representative of three independent donors. * P < 0.05, ** P < 0.01, and *** P < 0.001 versus control using ANOVA and Bonferroni 
post hoc test. Levels of PGE 2 /D 2 -PE are expressed as ratio analyte to internal standard (n = 3, mean ± SEM). 
is either rapidly transformed to thromboxane A 2 (TXA 2 ) 
or undergoes rearrangement to PGE 2 and D 2 ( 21, 22 ). 
The PGD synthase inhibitor HQL-79 did not block PGD 2 
formation (data not shown). Platelets express mPGES-2 
and cPGEs, which catalyze PGE 2 generation from PGH 2 , 
while mPGEs-1 is not detectable ( 21 ). Because no selec-
tive mPGES-2 and cPGEs inhibitors were available, involve-
ment of mPGES-2 and cPGEs could not be investigated. 
However, as free PGE 2 /D 2 ratios are similar for both plate-
lets and purifi ed COXs, their generation in platelets from 
PGH 2 prior to esterifi cation is most likely nonenzymatic 
( Figs. 2, 4G, H ). 
 The levels of these lipids are lower than for free PGs 
generated by platelets (28.1 ± 2.3 pg/2 × 10 8 platelets). 
However, they are not secreted from the cells and thus 
maybe concentrated in intracellular membranes, leading 
to considerably higher local concentrations. Furthermore, 
bioactive phospholipids can signal at extremely low con-
centrations; for example, PAF that can cause life-threatening 
airway infl ammation and infl ammatory activation at only 
10–1,000 pM concentrations ( 23 ). 
 PGE 2 /D 2 -PEs are generated within the fi rst 2 min of 
platelet activation, similar to the timescale for generation 
of free PGE 2 /D 2 ( Fig. 2A–D ). This indicates that forma-
tion is fast, coordinated, and a common event in response 
to several agonists. Their temporal generation (peaking 
around 10–30 min) could indicate further metabolism of 
esterifi ed PGs through PLA 2 hydrolysis or membrane re-
modeling pathways. The involvement of several signaling 
pathways indicates that this is a highly regulated event and 
further underscores their likely relevance to platelet biol-
ogy. All these act upstream, stimulating cPLA2 and COX-1 
and leading to generation of both free and esterifi ed 
PGE 2 /D 2 ( Scheme 2 ). Partial inhibition using thimerosal 
or triascin C coupled with in vitro experiments showing 
that COX-1 cannot directly oxidize PE suggests that PGE 2 /
D 2 -PEs form via reesterifi cation of newly formed PGE 2 /D 2 
( Scheme 2 ). This idea is also supported by the absence 
of 8-iso-PGE 2 and 11  -PGE 2 in LC-MS/MS chromato-
grams of PGs hydrolyzed from platelet PE (supplementary 
Fig. III G). This mechanism is fully consistent with aspirin 
inhibition in vitro and in vivo. Due to the short timescales 
involved and the inability of PGE 2 -d4 to become esterifi ed 
during platelet activation, it is likely that the proteins in-
volved in formation and reesterifi cation are closely associ-
ated such that AA hydrolysis, oxidation, and esterifi cation 
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are coordinated. We note that little is known regarding how 
oxidized fatty acids are esterifi ed into phospholipids, and 
whether the enzymes involved display preferences for dif-
ferent fatty acids or eicosanoids. To address this, in separate 
experiements, rat liver microsomes were used as a model 
system to study PGE 2 esterifi cation into PE. However, al-
though AA was effi ciently esterifi ed to either PE or PC, we 
were unable to detect PGE 2 -PE or -PC formation. We note 
that previous studies have shown that CoA independent 
transacylation reactions involved in ether lipid coupling are 
present in platelets but not rat liver microsomes, indicating 
that these systems likely contain very different complement 
of enzymes involved in fatty acid acylation ( 24 ). 
 The CoA-synthetases and lysophospholipid acyltrans-
ferases likely responsible for prostaglandin esterifi cation 
are localized at the endoplasmic reticulum, mitochondrial 
membrane, and peroxisomal membranes ( 25 ). Further-
more, COX-1 is localized to dense tubule structures in 
platelets ( 26 ). Thus, PGE 2 /D 2 -PE generation may occur 
on intracellular membranes ( Scheme 2 ). In this case, ex-
ogenously added PGE 2 must enter the platelet in order to 
be esterifi ed into PL. Thus, the lack of PGE 2 -d4 esterifi ca-
tion might also be due to an inability of platelets to take up 
this lipid through the absence of prostaglandin transport-
ers on the cell surface. To date, nothing is known regard-
ing expression of these proteins by platelets nor how they 
utilize oxidized fatty acids as substrates ( 27 ). 
 PGE 2 /D 2 -PEs belong to a growing family of phospholipid-
esterifi ed eicosanoids that have been described in platelets 
and other circulating vascular cells over the last 5 years. 
Up to now, all were generated enzymatically by LOXs and 
in platelets include families of PE and PC that contain 12-
hydroxyeicosatetraenoic acid (HETE) or 14-hydroxydo-
cosahexaenoic acid ( 13, 14 ). Additional LOX-derived 
PE-esterifi ed HETEs and keto-eicosatetraenoic acids have 
also been characterized in human neutrophils and mono-
cytes ( 3, 9, 10 ). Platelet HETE-phospholipids are also 
generated following PAR receptor triggering, but the in-
tracellular signaling cascade is partially distinct, involving 
sPLA 2 and extracellular calcium, but not PLC. This likely 
refl ects the different signaling pathways involved in 12-LOX 
versus COX-1 activation in platelets. 
 Unlike free eicosanoids, PGE 2 /D 2 -PEs remain mem-
brane-bound, indicating that they are likely to act locally 
( Fig. 3A,B ). This is similar to other enzymatically-generated 
oxPLs, such as HETE-phospholipids generated by LOXs, 
which regulate coagulation and immune cell signaling ( 3, 
9–11, 14 ). Oxidized PLs contain polar groups that can pro-
trude from the cell membrane surface. In the case of oxi-
dized PCs, this has led to the “Lipid Whisker Hypothesis”, 
where the  sn2 fatty acid derivatives coat the outside of the 
cell and act as scavenger receptor ligands ( 28 ). Due to their 
shape and polarity, PGE 2 and PGD 2 attached to PE are also 
likely to protrude from the intracellular membrane surface, 
 Scheme  2. Proposed mechanisms for formation of PGE 2 /D 2 -PE by human platelet COX-1. First, AA is 
oxidized by COX-1, then esterifi ed into PE. Formation of the lipids takes place in intracellular membranes 
where COX-1 and esterifi cation enzymes are localized. 
 at CARDIFF UNIVERSITY, on June 26, 2014
w
w
w
.jlr.org
D
ow
nloaded from
 
.html 
http://www.jlr.org/content/suppl/2013/07/24/jlr.M041533.DC1
Supplemental Material can be found at:
New prostaglandin phospholipids from platelets 3097
where they could interact with cytosolic proteins. Addi-
tionally, they could perturb membrane dynamics during 
platelet activation, through causing thinning or increasing 
water permeability, as shown to occur during chemical oxi-
dation of membranes ( 29 ). This may play a role in vesicula-
tion or degranulation, both events that involve signifi cant 
membrane perturbations. Once suffi cient quantities of 
these lipids can be generated, these ideas will all be tested in 
future studies. 
 In summary, COX-1 was found to generate a new family 
of oxPLs in platelets. The identifi cation of these new me-
tabolites opens the way for the study of how phospholipid-
bound PGs may regulate membrane behavior during 
platelet function and whether these might be a distinct tar-
get for modulation in platelet-dependent pathologies.  
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